The company has built a small and rugged system boasting 20-minute qPCR reactions and plans to expand the platform for other types of diagnostics.
The non-profit group is interested in improving manufacturing efficiencies to make point-of-care diagnostics more accessible.
Twelve hospitals will use the company's assays to screen vulnerable patients for genes from multi-drug resistant organisms.
Researchers hope to advance the technology to support an assay to help personalize oral cancer treatment by avoiding the development of mucositis.
The partners will leverage IME's rare cell isolation technology, a microchip containing a microfabricated filter membrane to isolate and enrich fetal cells from maternal blood.
The portable analyzer runs an RT-qPCR-based Ebola assay and takes about 75 minutes to detect the presence of the virus from whole blood.
NEW YORK (GenomeWeb News) – Molecular diagnostics company Rheonix today announced a joint development agreement with Life Technologies aimed at a molecular testing platform for the applied markets.
By Tony Fong
The partially reinstated US travel ban leaves space for uncertainty for researchers, Nature News says.
Researchers find a number of traits differ by sex and could affect mouse model studies, according to Reuters.
Tweaking the skin microbiome could help address some skin conditions, the New York Times reports.
In PNAS this week: DNA methylation profiles of tumor tissue, gene dynamics in prokaryotes, and more.